AstraZeneca entered into an exclusive global license agreement with China’s Dizal Pharmaceutical for the lung cancer ...

By Andrew Silver SHANGHAI, July 14 (Reuters) - Shares in China's Dizal Pharmaceutical rose 20% on Tuesday, after the ...

AstraZeneca has secured exclusive global rights to Dizal's Zegfrovy (sunvozertinib) through a new licensing agreement.

AstraZeneca (LSE:AZN) has agreed a new five year national partnership with YMCA of the USA to expand community based cancer education, screening, and survivorship support. The company also received US ...

AstraZeneca pays $600M for global rights to Dizal’s lung cancer drug Zegfrovy, boosting its oncology pipeline.

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has agreed to pay $600 million upfront to secure worldwide rights to a lung cancer pill ...

Nearly a decade after spinning out its Chinese research hub to form Dizal Pharmaceutical, AstraZeneca is paying up to $1.5 billion to buy a piece of the pipeline, securing exclusive global rights for ...

J&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.

The Food and Drug Administration (FDA) on Monday approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab deruxtecan or Dato-DXd) for adult patients with locally advanced or metastatic ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: An AstraZeneca sign is seen at the third China International Import Expo (CIIE) in Shanghai, China November 6, 2020.

AstraZeneca and Andrews introduce SCREEN, a limited-edition t-shirt designed to spark conversation and inspire action on the benefits of early detection. Erin Andrews wearing limited-edition SCREEN ...